The new candidat-médicament RCI001 actuellement under development delivers effets anti-inflammatoires through the selective modulation of multifunctional signaling molecules.
De plus, it has shown improvement in sécrétion lacrymale function, and is actuellement being developed as an eye drop dans le but de entering essais cliniques nationalally and internationally l'année prochaine. RCI001 played a key role in being selected for the 'R&D Rediscovery Project' and other programs.